Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study

被引:25
|
作者
Rhee, Harin [1 ,2 ]
Berenger, Brendan [1 ]
Mehta, Ravindra L. [1 ]
Macedo, Etienne [1 ]
机构
[1] Univ Calif San Diego, Dept Med, 0892 UCSD Med Ctr,9500 Gilman Dr, La Jolla, CA 92037 USA
[2] Pusan Natl Univ, Sch Med, Dept Internal Med, Pusan, South Korea
基金
美国国家卫生研究院;
关键词
CONTINUOUS RENAL REPLACEMENT; SYSTEMIC HEPARIN ANTICOAGULATION; CRITICALLY-ILL PATIENTS; CARE;
D O I
10.1053/j.ajkd.2021.01.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Regional citrate anticoagulation (RCA) is the preferred anticoagulation method for continuous kidney replacement therapy (CKRT) recommended by KDIGO. Limited availability of calcium-free solutions often imposes challenges to the implementation of RCA for CKRT (RCA-CKRT). The principal purpose of this study was to characterize the outcomes of RCA-CKRT using calcium-containing solutions. Study Design: Retrospective cohort study. Setting & Participants: We evaluated the safety and efficacy of RCA-CKRT with calcium-containing dialysate and replacement fluid used for 128 patients. A total of 571 filters and 1,227 days of CKRT were analyzed. Exposures: Liver disease, sepsis in the absence of liver disease, and sepsis with liver disease. Outcomes: Filter life and metabolic complications per 100 CKRT days. Analytical Approach: Linear mixed-effects model and generalized linear mixed-effects models. Results: The majority of patients were male (91; 71.1%), 32 (25%) had liver disease, and 29 (22.7%) had sepsis without liver disease. Median filter life was 50.0 (interquartile range, 22.0-118.0) hours, with a maximum of 322 hours, and was significantly lower (33.5 [interquartile range, 17.5-60.5] h) in patients with liver disease. Calcium-containing replacement solutions were used in 41.6% of all CKRT hours and reduced intravenous calcium requirements by 31.7%. Hypocalcemia (ionized calcium <0.85 mmol/L) and hypercalcemia (total calcium >10.6 mg/dL) were observed in 6.0 and 6.7 per 100 CKRT days, respectively. Citrate accumulation was observed in 13.3% of all patients and was associated with metabolic acidosis in 3.9%, which was not significantly different in patients with liver disease (9.3%; P = 0.2). Limitations: Lack of control groups that used calcium-free dialysate and replacement solutions with RCA-CKRT. Possible overestimation of filter life from incomplete data on cause of filter failure. Conclusions: Our study suggests that RCA-CKRT with calcium-containing solutions is feasible and safe in critically ill patients, including those with sepsis and liver disease.
引用
收藏
页码:550 / U70
页数:11
相关论文
共 50 条
  • [41] Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation
    Swartz, R
    Pasko, D
    O'Toole, J
    Starmann, B
    CLINICAL NEPHROLOGY, 2004, 61 (02) : 134 - 143
  • [42] IS REGIONAL CITRATE BETTER THAN HEPARIN FOR ANTICOAGULATION IN CONTINUOUS RENAL REPLACEMENT THERAPY?
    Rajabalan, Ajai
    Sunil, Sriram
    Ridley, Emerson
    Davis, John
    Vidyasagaran, Thara
    Suarez, Jonathan
    Cobb, Jason
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 664 - 664
  • [43] CONTINUOUS RENAL REPLACEMENT THERAPY WITH REGIONAL CITRATE ANTICOAGULATION IN NEWBORNS AND SMALL CHILDREN
    Gubensek, Jakob
    Medved, Bojan
    Persic, Vanja
    Vajdic, Barbara
    Premru, Vladimir
    Buturovic-Ponikvar, Jadranka
    Pavcnik, Maja
    Vidmar, Ivan
    Ponikvar, Rafael
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 : 290 - 290
  • [44] Regional citrate anticoagulation with continuous renal replacement therapy: a rare cause of hypercalcemia
    Needleman, Leor
    Hughes, Michael S.
    Mohty, Ralph Mohammed
    Fatehi, Pedram
    Sellmeyer, Deborah
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 120 - 120
  • [45] Regional citrate anticoagulation with calcium replacement in pediatric apheresis
    Sigler, Katie
    Lee, Ji
    Srivaths, Poyyapakkam
    JOURNAL OF CLINICAL APHERESIS, 2018, 33 (03) : 274 - 277
  • [46] Regional citrate anticoagulation for continuous renal replacement therapy without post-filter monitoring of ionized calcium
    Fulop, Tibor
    Salim, Sohail Abdul
    Zsom, Lajos
    JOURNAL OF RENAL INJURY PREVENTION, 2018, 7 (03): : 139 - 143
  • [47] Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy
    Mai J. Miyaji
    Kentaro Ide
    Kohei Takashima
    Mikiko Maeno
    Kelli A. Krallman
    Danielle Lazear
    Stuart L. Goldstein
    Pediatric Nephrology, 2022, 37 : 2733 - 2742
  • [48] CITRATE ANTICOAGULATION FOR CONTINUOUS RENAL REPLACEMENT THERAPY IN NEONATES WITH ACUTE KIDNEY INJURY
    Soltysiak, Jolanta
    Malke, Anna
    Warzywoda, Alfred
    Blumczynski, Andrzej
    Silska-Dittmar, Magdalena
    Musielak, Anna
    Ostalska-Nowicka, Danuta
    Zachwieja, Jacek
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 426 - 427
  • [49] Citrate Anticoagulation for Continuous Kidney Replacement Therapy: An Embarrassment of RICH-es
    Szamosfalvi, Balazs
    Yessayan, Lenar T.
    Heung, Michael
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (01) : 146 - 150
  • [50] Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy
    Miyaji, Mai J.
    Ide, Kentaro
    Takashima, Kohei
    Maeno, Mikiko
    Krallman, Kelli A.
    Lazear, Danielle
    Goldstein, Stuart L.
    PEDIATRIC NEPHROLOGY, 2022, 37 (11) : 2733 - 2742